tg-me.com/venture_tg/4987
Last Update:
Raising capital in 2024 has been challenging for many venture capital firms, but Dimension Capital has experienced significant success with its second fund. Within just two years of launching, Dimension raised an oversubscribed $500 million fund, surpassing its $400 million target. Founders Zavian Dar, Adam Goulburn, and Nan Li credit their appeal to a unique focus on investing at the intersection of life sciences and technology, particularly in AI-driven drug discovery.
Since its inception in 2022, Dimension has invested in around 20 companies, half of which remain in stealth mode. Notable portfolio companies include Chai Discovery, which is developing an open-source AI model for drug discovery, and Enveda Biosciences, which raised $130 million for its AI-based medicine development.
Originally focused on early-stage investments, Dimension has shifted to a stage-agnostic approach, allowing it to invest anywhere from $1 million to over $30 million across various development stages, including publicly traded companies. The firm prioritizes biotech startups with teams that include significant computational expertise, ensuring a collaborative environment between biologists and tech specialists.
Dimension's investor base comprises endowments, hospitals, and research institutions, and the firm is impressed by the caliber of entrepreneurs entering the life sciences sector, highlighting the ambition and technical expertise of the new founders.
